Who are anti-CD 25 mAb, Sirolimus, MMF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): anti-CD25 rhMAb, Thymoglobulin (ATG), Thymoglobuline Genzyme, Basiliximab treatment, tacrolimus, ATG, Individual ATG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-cd-25-mab-sirolimus-mmf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

anti-CD 25 mAb, Sirolimus, MMF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

anti-CD 25 mAb, Sirolimus, MMF (anti-CD 25 mAb, Sirolimus, MMF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Immunology.

phase 3 Monoclonal antibody CD25 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

anti-CD 25 mAb, Sirolimus, MMF (anti-CD 25 mAb, Sirolimus, MMF) — University of Regensburg. Anti-CD 25 mAb targets and binds to the CD25 receptor on T cells, preventing their activation and proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
anti-CD 25 mAb, Sirolimus, MMF TARGET	anti-CD 25 mAb, Sirolimus, MMF	University of Regensburg	phase 3	Monoclonal antibody	CD25
anti-CD25 rhMAb	anti-CD25 rhMAb	Peking University People's Hospital	marketed	CD25 antagonist monoclonal antibody	CD25 (IL-2 receptor alpha chain)
Thymoglobulin (ATG)	Thymoglobulin (ATG)	M.D. Anderson Cancer Center	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR)
Thymoglobuline Genzyme	Thymoglobuline Genzyme	University Hospital, Basel, Switzerland	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others)
Basiliximab treatment	Basiliximab treatment	Nantes University Hospital	marketed	Monoclonal antibody; IL-2 receptor antagonist	CD25 (IL-2 receptor alpha chain)
tacrolimus, ATG	tacrolimus, ATG	University Hospital, Toulouse	marketed	Calcineurin inhibitor and polyclonal antithymocyte antibody	Calcineurin (tacrolimus); T-cell surface antigens including CD2, CD3, CD4, CD8, CD25 (ATG)
Individual ATG	Individual ATG	The First Affiliated Hospital of Soochow University	marketed	Polyclonal antithymocyte globulin (immunosuppressant)	T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). anti-CD 25 mAb, Sirolimus, MMF — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd-25-mab-sirolimus-mmf. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab